Japan approves Incyte Minjuvi for DLBCL | INCY Stock News

Incyte Japan wins MHLW approval for Minjuvi combo in 2L+ FL | INCY ...

Incyte Wins FDA Approval for Once-Daily Jakafi XR | INCY Stock News

Incyte wins CHMP backing for Zynyz in advanced SCAC | INCY Stock News

Incyte Announces 50+ Abstracts for 2025 ASH, mutCALR Data | INCY Stock News

Incyte gets CHMP nod for Opzelura in adult eczema | INCY Stock News

Incyte Phase 3 tafasitamab data featured at ASCO | INCY Stock News

Incyte 54-week Phase 3 HS data back povorcitinib | INCY Stock News

Incyte reports rapid MF, ET responses with INCA033989 | INCY Stock News

Incyte posts 81% bleed cut in Phase 1/2 VWD trial | INCY Stock News

Incyte to buy Vega Therapeutics in up to $2.0B deal | INCY Stock News

Incyte closes Vega buy, adds Phase 3 VGA039 | INCY Stock News

INCY Stock Price, News & Analysis | Incyte

Incyte posts positive Phase 1 data for MF mutCALR antibody | INCY Stock ...

Incyte tafasitamab combo cuts progression/death risk 25% | INCY Stock News

Incyte Opzelura posts 84.3% EASI75 at Week 24 | INCY Stock News

Eli Lilly gets CHMP backing for Olumiant in teen AA | INCY Stock News

Incyte (INCY) Stock Dips Despite Japan's Green Light for Minjuvi in ...

Japan Approves Minjuvi for Relapsed or Refractory Diffuse Large B-Cell ...

Incyte (INCY) Stock News & Updates | StockTitan

Incyte's INCA033989 gets FDA Breakthrough status in ET | INCY Stock News

Incyte, Mirum to present pivotal FOP Phase 2 data at ENDO | INCY Stock News

Incyte Shows Phase 1 Data for INCA33890, INCB161734 at ESMO | INCY ...

Star Therapeutics to present VGA039 Phase 1/2 data | INCY Stock News

COFEPRIS Approves Knight's Minjuvi for DLBCL Treatment

Incyte, Mirum Phase 2 FOP data; FDA Priority Review | INCY Stock News

Incyte Teams With Winnie Harlow to Elevate Vitiligo Voices | INCY Stock ...

Incyte’s Minjuvi secures first Japan approval for follicular lymphoma ...

InnoCare Pharma's Minjuvi Gains NMPA Approval for DLBCL Treatment ...

Japan's MHLW Approves Minjuvi (tafasitamab) Plus Lenalidomide for ...

EC Approves Incyte’s Minjuvi Combo for Follicular Lymphoma - API Data ...

Incyte Secures AI Drug Discovery Platform in $620M Genesis Deal | INCY ...

FDA Approves Incyte's Zynzy for Metastatic MCC | PatSnap

Incyte Expands Moments of Clarity with 6 New Patient Stories | INCY ...

Incyte Stock Sinks as Sales Forecast for Key Drugs Falls Short

Japan Approves Incyte’s (NASDAQ:INCY) Zynyz for First-Line Anal Cancer

Japan government approves record 122 trillion yen budget - Latest News

INCY Financials: Income Statement, Balance Sheet & Cash Flow | Incyte Corp

Incyte details pipeline and product portfolio | INCY Annual Report (10-K)

INCY Stock WEDNESDAY UPDATE! (massive news!) Incyte stock trading to go ...

Japan Approves New Overtourism Measures | DMM英会話 デイリーニュース

Incyte inks $25M deal for cancer drug

EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi - The Globe ...

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in ...

The Bull Case For Incyte (INCY) Could Change Following Positive ...

InnoCare Secures China's NMPA Approval for Minjuvi Combo in Treating ...

Incyte (INCY) Receives Adjusted Price Target from TD Cowen | INC

EC approves Incyte’s Minjuvi

Dlbcl 18F Fludarabine PET For Lymphoma Imaging: First In Humans Study

Dlbcl 18F Fludarabine PET For Lymphoma Imaging: First In Humans Study

Options for the treatment of second-line DLBCL

Australia approves MINJUVI® (tafasitamab) for treatment of relapsed or ...

Are Wall Street Analysts Predicting Incyte Stock Will…

Blenrep, Minjuvi, Zynyz, and More New Drugs Hit Japan Market | PHARMA JAPAN

China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL

FinancialContent - Why Incyte (INCY) Stock Is Nosediving

Glofitamab Approved for Relapsed Refractory DLBCL in Canada - Media ...

Incyte (INCY) Stock Up 3.2% After TD Cowen Raises Price Target to $128 ...

Incyte Stock Collapses On Its Shattered $750 Million Escient Takeover ...

Idelalisib Dlbcl [Full text] Development of venetoclax for therapy of ...

FDA fast-tracks Incyte drug for rare blood cancer (INCY:NASDAQ ...

Japan Cabinet Approves Record ¥122.3 Trillion Budget Amid Rising Debt ...

Japan approves major defense overhaul in dramatic policy shift - The ...

Japan approves scrapping a ban on lethal weapons exports in a change of ...

Incyte (INCY): Buy, Sell, or Hold Post Q3 Earnings? — TradingView News

Incyte wins EU backing for MacroGenics-partnered cancer drug (INCY ...

Incyte (NASDAQ:INCY) Reports Strong Q2 | FinancialContent

EC approves Minjuvi+lenalidomide to treat relapsed or refractory ...

Incyte Q1 Revenue Zooms 21% to $1.27 Billion

Incyte Logo The Incyte Ingenuity Awards In GVHD™ And Vitiligo

EC approves Minjuvi+lenalidomide to treat relapsed or refractory ...

Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic ...

Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell ...

Japan's MHLW approves Minjuvi® (tafasitamab) in combination with ...

Anticipating pricing and reimbursement for newly approved products ...

Cells | Free Full-Text | Immunotherapy of Hematological Malignancies of ...

Incyte Could Stoke M&A Fire On 'Deep And Durable' Melanoma Drug Results ...

$INCY -0.56% today MINJUVI® (tafasitamab) for Relapsed or Refractory ...

Incyte Announces Health Canada Approval of Minjuvi® in Combination with ...

Prelude Therapeutics Secures FDA Clearance for Incyte-Partnered Cancer ...

Merck Carries Incyte On Keytruda Coattails In 4 'Hot' Tumors: Leerink ...

Incyte Corporation 2025 Q1 - Results - Earnings Call Presentation ...

Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan ...

Incyte (INCY) Q2 Earnings: What To Expect

DLBCL lymphoma. Prof. Gil: Previously used CAR-T therapy may give ...

Incyte Corporation (INCY) Presents at The 67th American Society of ...

Incyte's Opzelura Wins FDA Approval for Children 2-11 with Eczema ...

Faithward Advisors LLC Takes $4.45 Million Position in Incyte ...

What to Expect From Incyte's Next Quarterly Earnings Report | Nasdaq

Incyte Logo The Incyte Ingenuity Awards In GVHD™ And Vitiligo

BPAS - Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads ...

INCY (Incyte) Backtesting: A Comprehensive Analysis and Guide • Vestinda

Japan scraps a ban on lethal weapons exports in a change of its postwar ...

다카이치 "다케시마는 日영토…의연하게 대응" 또 억지 주장(종합) | 연합뉴스

Incyte (INCY) Positioned To Offset Patent Cliff Risks, Analysts ...

Bank of America Securities Maintains a Buy Rating on Incyte Corporation ...

FinancialContent - Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ ...

诺诚健华宣布Tafasitamab联合来那度胺治疗复发/难治DLBCL在博鳌乐城开出首方医药新闻-ByDrug-一站式医药资源共享中心-医药魔方

MINJUVI® 200 mg Pulver für ein Konzentrat zur Herstellung einer ...

Xencor, Inc. - Drug pipelines, Patents, Clinical trials - Synapse

展品详情

Monjuvi(Tafasitamab)治疗复发或难治性DLBCL的实际临床数据解析 - 香港致泰药业

Safety and efficacy of tafasitamab with or without lenalidomide added ...

【02:12 即時新聞】Incyte (INCY) 股價大漲逾5% 歐盟核准Minjuvi新適應症利多激勵

诺诚健华1.2亿引入CD19单抗tafasitamab|Incyte|细胞淋巴瘤|DLBCL|CD19|难治性|依赖性|单抗|抗体|-健康界

What Are Possible Causes Of B Cell Lymphoma – BIKTI

诺诚健华1.2亿引入CD19单抗tafasitamab|Incyte|细胞淋巴瘤|DLBCL|CD19|难治性|依赖性|单抗|抗体|-健康界

二线DLBCL药物对比 - 2024年06月 - 行业研究数据 - 小牛行研

【塔法西他滨单抗,Tafasitamab,Minjuvi（欧洲版）】说明书_代购价格_印度直邮-印度全球药房

Jefferies Initiates Incyte(INCY.US) With Hold Rating, Announces Target ...

Is Incyte's Growth Story Still Attractive After Its 2025 Rally and DCF Gap?

Jakafi XR FDA Approval: Incyte's Once-Daily Ruxolitinib

UN Nuclear Agency chief to visit Fukushima Plant to see final ...

Car T Cells Effets Secondaires _ Car T Cells Avis – AYWFBP

tm231988-1_nonfiling - none - 26.3283252s

STARGLO Trial: Glofitamab Plus GemOx Yields 59% Risk Reduction, Median ...

Contact Us - Sherbrooke Record - Earnings Preview: What To Expect From ...

Perplexity Finance